Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.47 |
| ▸ | PTGES2 | Q9H7Z7 | 4/20 | 0.37 |
| ▸ | F10 | P00742 | 8/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | CA9 | Q16790 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4115216 | 0.82 | PTGES (0.47) | PTGESPTGES2F10CA2CA9 | |
| SCHEMBL979478 | 0.78 | PTGES (0.48) | PTGESPTGES2F10CA2CA9 | |
| SCHEMBL980249 | 0.74 | PTGES (0.75) | PTGESPTGES2CA2CA9CA12 | |
| SCHEMBL979255 | 0.74 | PTGES (0.60) | PTGESPTGES2CA2CA9CA12 | |
| SCHEMBL9588168 | 0.72 | CA2 (0.57) | PTGES2CA2CA9CA12CA1 | |
| SCHEMBL978293 | 0.70 | PTGES (0.49) | PTGESPTGES2 | |
| SCHEMBL979195 | 0.70 | PTGES (0.58) | PTGESPTGES2CA2CA9CA1 | |
| SCHEMBL13850991 | 0.69 | F10 (0.45) | PTGESPTGES2F10CA2CA9 | |
| SCHEMBL978262 | 0.69 | PTGES (0.45) | PTGESPTGES2CA2CA9CA12 | |
| SCHEMBL979262 | 0.68 | PTGES (0.72) | PTGESCA2CA9CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2011-01-27 | — | — | US | claimed |
| WO-2009064250-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 065 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | CYP2D6, PTGER1, CYP2B6 | PTGES 13/4885PTGES2 26/4885F10 3272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.